Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Maurizio Pantalena"'
Autor:
Flavio Valiante, Manuel Zorzi, Bastianello Germanà, Carmelo Luigiano, Arrigo Arrigoni, Cesare Hassan, Maurizio Pantalena, Saverio Alicante, Paola Mantellini, Fabio Monica, Carlo Senore, Beatrice Mallardi, Giulio Antonelli, Grazia Grazzini, Federico Iacopini, Erik Rosa-Rizzotto, Tamara Meggiato, Gianmarco Bulighin, Jessica Battagello
Publikováno v:
Endoscopy. 54:138-147
Background The Endocuff Vision device (Arc Medical Design Ltd., Leeds, UK) has been shown to increase mucosal exposure, and consequently adenoma detection rate (ADR), during colonoscopy. This nationwide multicenter study assessed possible benefits an
Autor:
Sergio Vigneri, Rosanna Termini, Gioacchino Leandro, Salvatore Badalamenti, Maurizio Pantalena, Vincenzo Savarino, Francesco Di Mario, Giuseppe Battaglia, Giuseppe Sandro Mela, Alberto Pilotto, Mario Plebani, Giovanni Davi
Publikováno v:
New England Journal of Medicine. 333:1106-1110
Patients with reflux esophagitis have a high rate of relapse within one year after therapy is discontinued.We enrolled 175 adults with endoscopy-confirmed reflux esophagitis in a prospective study comparing five maintenance therapies. All the patient
Autor:
Giancarlo Parisi, Maurizio Pantalena, Giorgio Verdianelli, Gioacchino Leandro, M. Carrara, Gianni Tafner, Alessandra Faedo, Fabrizio Cardin, Marco Marino, Dario Goldin, Maurizio Zilli, Enrico Bottona
Publikováno v:
Digestive diseases and sciences. 50(6)
The effects of partially hydrolyzed guar gum (PHGG) were compared in patients with irritable bowel syndrome, at 10 g/day (N = 40) and 5 g/day (N = 46) for 12 weeks. Gastrointestinal symptoms (GSRS), quality of life (SF-36), and psychological symptoms
Autor:
Maurizio Pantalena, Sandro Vento, Valerio Mecenero, Fabio Lugoboni, Gianluca Quaglio, Alessandro Lechi, Alessandro Pani, Augusto Accordini, Carlo Bossi, Paolo Mezzelani, Marco Faccini, Margherita Residori
Publikováno v:
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 32(10)
In a study of 497 injection drug users who had isolated presence of antibody to hepatitis B core antigen (anti-HBc) at the time of enrollment, 404 (81%) retained this condition after a mean of 49 months of follow-up, during which time no new hepatiti
Autor:
Zagni, I., Minola, E., Felder, M., Rovere, P., Carlotto, A., Suppressa, S., Miracolo, A.M., Paternoster, C., Rizzo, C., Rossin, A., Benedetti, P., Dilani, S., Chiara, Ferrara, Paolo, Costa, Tosca, Bertin, Maurizio, Pantalena, Federica, Fabris, Lorenzo, Lomonaco, Giuseppe, Mazzella, Sergio, Boccia, Renato, Marin, Lisa, Ribero Maria, Alessandro, Tagger, Giovanna, Fattovich
Publikováno v:
In Digestive and Liver Disease 2002 34 Supplement 1:A61-A61